Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.
Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM; PanCareLIFE Consortium; and the CPNDS Consortium. Meijer AJM, et al. Among authors: brooks b. NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z. NPJ Precis Oncol. 2021. PMID: 34262104 Free PMC article.
Genetic markers of cisplatin-induced hearing loss in children.
Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR. Carleton BC, et al. Among authors: brooks b. Clin Pharmacol Ther. 2014 Sep;96(3):296-8. doi: 10.1038/clpt.2014.92. Clin Pharmacol Ther. 2014. PMID: 25141953
A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.
Clemens E, Brooks B, de Vries ACH, van Grotel M, van den Heuvel-Eibrink MM, Carleton B. Clemens E, et al. Among authors: brooks b. PLoS One. 2019 Feb 14;14(2):e0210646. doi: 10.1371/journal.pone.0210646. eCollection 2019. PLoS One. 2019. PMID: 30763334 Free PMC article.
Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR. Carleton BC, et al. Among authors: brooks b. Clin Pharmacol Ther. 2014 Mar;95(3):253. doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5. Clin Pharmacol Ther. 2014. PMID: 24193170 No abstract available.
Economic impact of a genetic test for cisplatin-induced ototoxicity.
Dionne F, Mitton C, Rassekh R, Brooks B, Ross C, Hayden M, Carleton B. Dionne F, et al. Among authors: brooks b. Pharmacogenomics J. 2012 Jun;12(3):205-13. doi: 10.1038/tpj.2011.15. Epub 2011 Apr 19. Pharmacogenomics J. 2012. PMID: 21502965
GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study.
D'Souza P, Farmer C, Johnston JM, Han ST, Adams D, Hartman AL, Zein W, Huryn LA, Solomon B, King K, Jordan CP, Myles J, Nicoli ER, Rothermel CE, Mojica Algarin Y, Huang R, Quimby R, Zainab M, Bowden S, Crowell A, Buckley A, Brewer C, Regier DS, Brooks BP, Acosta MT, Baker EH, Vézina G, Thurm A, Tifft CJ. D'Souza P, et al. Among authors: brooks bp. Genet Med. 2024 Apr 16:101144. doi: 10.1016/j.gim.2024.101144. Online ahead of print. Genet Med. 2024. PMID: 38641994
1,858 results